Does BELANTAMAB MAFODOTIN Cause Therapy partial responder? 19 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Therapy partial responder have been filed in association with BELANTAMAB MAFODOTIN (Blenrep). This represents 0.8% of all adverse event reports for BELANTAMAB MAFODOTIN.
19
Reports of Therapy partial responder with BELANTAMAB MAFODOTIN
0.8%
of all BELANTAMAB MAFODOTIN reports
3
Deaths
1
Hospitalizations
How Dangerous Is Therapy partial responder From BELANTAMAB MAFODOTIN?
Of the 19 reports, 3 (15.8%) resulted in death, 1 (5.3%) required hospitalization, and 3 (15.8%) were considered life-threatening.
Is Therapy partial responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BELANTAMAB MAFODOTIN. However, 19 reports have been filed with the FAERS database.
What Other Side Effects Does BELANTAMAB MAFODOTIN Cause?
Keratopathy (788)
Visual acuity reduced (708)
Death (499)
Plasma cell myeloma (380)
Dry eye (359)
Night blindness (317)
Photophobia (183)
Foreign body sensation in eyes (151)
Vision blurred (134)
Ocular toxicity (94)
What Other Drugs Cause Therapy partial responder?
CYCLOPHOSPHAMIDE (1,397)
RITUXIMAB (1,219)
DEXAMETHASONE (1,199)
PREDNISONE (1,176)
PEMBROLIZUMAB (1,125)
CARBOPLATIN (1,096)
DOXORUBICIN (834)
METHOTREXATE (775)
VINCRISTINE (707)
ETOPOSIDE (670)
Which BELANTAMAB MAFODOTIN Alternatives Have Lower Therapy partial responder Risk?
BELANTAMAB MAFODOTIN vs BELANTAMAB MAFODOTIN-BLMF
BELANTAMAB MAFODOTIN vs BELATACEPT
BELANTAMAB MAFODOTIN vs BELIMUMAB
BELANTAMAB MAFODOTIN vs BELINOSTAT
BELANTAMAB MAFODOTIN vs BELUMOSUDIL